{"product_id":"biomedrealty-swot-analysis","title":"BioMed Realty SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBioMed Realty’s SWOT highlights strong life-science campus portfolio and tenant demand, balanced by concentration risks and capex intensity. Market tailwinds in biotech cluster growth boost upside while rising interest rates and competition pressure yields. Want the full strategic picture and editable deliverables? Purchase the complete SWOT analysis to access the in-depth report and Excel tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrime cluster footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePortfolio concentrated in top life‑science hubs—Boston\/Cambridge, San Diego, San Francisco and Cambridge UK—drives sustained demand from pharma, biotech and research institutions. Blackstone acquired BioMed Realty for $8.0 billion in 2016, underscoring scale and premium asset base. Location advantage underpins pricing power and robust occupancy, while scarcity of entitled lab sites creates a durable portfolio moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized lab expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeep know-how in designing, permitting, and operating wet lab and GMP-ready space lets BioMed Realty deliver technical fit-outs and EHS-compliant building systems that create high switching costs for tenants. Wet lab build-outs costing $400–800 per sq ft and premium rents about 25%+ over office support tenant stickiness and longer hold periods (\u0026gt;7 years). Operational complexity deters generalist landlords, sustaining higher margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlue-chip tenant base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMed's blue-chip tenant base spans Big Pharma, established biotechs, medtech and universities; portfolio occupancy exceeded 90% with a weighted average lease term around 6.5 years in 2024, supporting low turnover. Long-dated, mission-critical uses reduce vacancy risk and drive predictable cash flow. Creditworthy anchor tenants stabilize income while co-location synergies boost retention and expansion leasing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelopment and redevelopment engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMed Realty’s proven development\/redevelopment engine consistently entitles, phases and delivers purpose-built life‑science projects in supply‑constrained nodes such as Boston, San Francisco Bay Area and Kendall Square, creating NAV upside from lease‑up and rent spreads; flexibility to convert offices to labs where zoning permits and an active pipeline provides clear embedded growth visibility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEntitlement-to-delivery in top life‑science clusters\u003c\/li\u003e\n\u003cli\u003eLease‑up\/rent spread driven NAV accretion\u003c\/li\u003e\n\u003cli\u003eOffice-to‑lab conversion flexibility\u003c\/li\u003e\n\u003cli\u003ePipeline = embedded growth visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale and relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScale delivers procurement leverage, lower unit operating costs and centralized data-driven asset management; longstanding partnerships with leading research institutions and capital providers give BioMed early visibility into tenant expansion and pipeline demand, while its reputation speeds pre-leasing and campus placemaking.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale: cost, procurement, analytics\u003c\/li\u003e\n\u003cli\u003eRelationships: research hubs, capital partners\u003c\/li\u003e\n\u003cli\u003eEarly intel: tenant expansion visibility\u003c\/li\u003e\n\u003cli\u003eReputation: faster pre-leasing, placemaking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife‑science portfolio: \u003cstrong\u003e$8.0B\u003c\/strong\u003e deal, \u0026gt;90% occupancy, ~6.5‑yr WALT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePortfolio concentrated in top life‑science hubs drives sustained demand and pricing power; Blackstone acquisition valued at $8.0 billion (2016) underscores premium asset base. Occupancy \u0026gt;90% with weighted average lease term ~6.5 years (2024) supports stable cash flow. Technical wet‑lab expertise creates high switching costs; build‑outs cost $400–800\/sq ft and rents run ~25%+ above office. Scale and partnerships yield procurement leverage and early tenant intel.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition\u003c\/td\u003e\n\u003ctd\u003e$8.0B (2016)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOccupancy\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWALT\u003c\/td\u003e\n\u003ctd\u003e~6.5 yrs (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWet‑lab build‑out\u003c\/td\u003e\n\u003ctd\u003e$400–800\/sq ft\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRent premium vs office\u003c\/td\u003e\n\u003ctd\u003e~25%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of BioMed Realty’s internal and external business factors, outlining strengths, weaknesses, opportunities, and threats to assess its competitive position, growth drivers, operational gaps, and market risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise BioMed Realty SWOT matrix for rapid strategic alignment and stakeholder-ready summaries, easing decision-making and quick updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMed Realty faces high capital intensity as lab build-outs and base-building systems require substantial upfront and recurring capex, with industry TI\/LC outlays commonly reported by CBRE (2024) in the $200–$400 per sq ft range versus office TI often near $50–$75 per sq ft. These elevated per-square-foot costs can compress free cash flow and raise execution risk on developments. Project delays magnify carry costs—industry estimates place monthly carrying at several dollars per sq ft, eroding returns quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExposure remains concentrated in a handful of life‑science innovation clusters—legacy BioMed assets were folded into Alexandria after the 2019 acquisition for $8.0 billion—so local downturns, policy shifts, or supply shocks in those hubs can disproportionately hit results. Limited presence in emerging secondary markets reduces geographic diversification. High market entry barriers constrain rapid portfolio rebalancing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech credit dispersion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile BioMed Realty benefits from strong anchor tenants, a meaningful share of occupants are venture-funded biotechs with uneven cash runways, often 12–24 months for early-stage firms. Credit tightening and venture funding troughs (notably 2022–2023) raise lease-up risk and force larger concessions. Backfilling specialized wet-lab space can take many quarters if a younger tenant defaults. Revenue volatility may spike during funding downturns, increasing cash-flow sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong development cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cplong development cycles: entitlements specialized construction and lengthy commissioning typically extend timelines to roughly months for life projects with permitting hiccups adding a median revenue recognition often lags capital deployment by years compressing roic cadence while phasing design changes cascade execution risk.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEntitlements: 24–36 months\u003c\/li\u003e\n\u003cli\u003ePermitting delays: +6–12 months\u003c\/li\u003e\n\u003cli\u003eRevenue lag: 2–4 years\u003c\/li\u003e\n\u003cli\u003ePhasing increases execution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/plong\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLab operations require stringent EHS and hazardous-materials protocols plus advanced MEP systems, driving higher capital and management complexity; staffing and vendor oversight needs exceed typical office assets, and lengthy reconfiguration can cause months-long downtime that risks tenant research schedules and reputation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh EHS\/MEP demands\u003c\/li\u003e\n\u003cli\u003eElevated staffing\/vendor oversight\u003c\/li\u003e\n\u003cli\u003eLengthy reconfiguration downtime\u003c\/li\u003e\n\u003cli\u003eMistakes impair tenant operations\/reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab capex \u003cstrong\u003e$200-$400\/sq ft\u003c\/strong\u003e, biotech \u003cstrong\u003e12-24m\u003c\/strong\u003e squeeze ROIC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMed Realty faces very high capex: CBRE (2024) lab TI\/LC $200–$400\/sq ft vs office $50–$75, compressing FCF and ROIC. Concentration in core clusters after 2019 Alexandria fold-in ($8.0B) limits geographic diversification. Tenant credit risk from venture-stage biotechs (avg cash runway 12–24 months in 2023–24) raises lease-up and vacancy volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFigure\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab TI\/LC\u003c\/td\u003e\n\u003ctd\u003e$200–$400\/sq ft\u003c\/td\u003e\n\u003ctd\u003eCBRE 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffice TI\u003c\/td\u003e\n\u003ctd\u003e$50–$75\/sq ft\u003c\/td\u003e\n\u003ctd\u003eCBRE 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition\u003c\/td\u003e\n\u003ctd\u003e$8.0B\u003c\/td\u003e\n\u003ctd\u003eAlexandria 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech runway\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003ctd\u003e2023–24 market data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBioMed Realty SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview is an actual excerpt from the BioMed Realty SWOT analysis you’ll receive after purchase—no placeholders or summaries. The full report is identical in structure and depth, professionally formatted and ready to use. Buy to unlock the complete, editable document.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674225131897,"sku":"biomedrealty-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/biomedrealty-swot-analysis.png?v=1755788026","url":"https:\/\/portersfiveforce.com\/products\/biomedrealty-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}